• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Pfizer > January 27, 2010

      Pfizer, Like Much of Big Pharma, Pushes Further Into Generics

      Posted AtBlogs.wsj.com

      The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal.

      Pfizer’s been moving in this direction for a while now. An “established products” division the company set up back in 2008 to focus on off-patent drugs now sells some 600 products, and the company has cut several deals like the one announced today. (See the 2008 deal with Aurobindo India, for example.)

      Growth has slowed in the branded-drugs business, and the push is on in the developed world to slow the rise of health-care costs. Both of those factors are driving many of the big names in the drugs business to move further into generics. In the past few years, GlaxoSmithKline made a deal with the South African drug-maker Aspen to sell off-patent drugs in the developing world, Sanofi-Aventis bought several generics companies, and Merck set up a unit to sell copies of off-patent biotech drugs.


      Share this Article!

    Back to top^